ArticleFrontiers in neuroscience2026
Differential effects of cannabidiol on inhibitory avoidance memory reconsolidation and consolidation are associated with distinct hippocampal proBDNF and BDNF signaling profiles.
Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cannabidiol (CBD), a major non-psychoactive constituent of Methods: Mice were subjected to the IA task and administered CBD at different doses during either the reconsolidation or consolidation phase. To examine the involvement of tropomyosin receptor kinase (Trk) signaling, the Trk receptor antagonist K252a was co-administered with CBD. In addition, anisomycin (ANI) was used to induce impairments in IA memory consolidation. Hippocampal levels of pro-brain-derived neurotrophic factor (proBDNF) and mature brain-derived neurotrophic factor (BDNF) were measured to investigate the molecular mechanisms underlying CBD-mediated effects. Results: CBD impaired IA memory reconsolidation in a dose-dependent manner, and this effect was abolished by K252a. During reconsolidation, CBD selectively reduced hippocampal proBDNF levels without altering mature BDNF expression. In contrast, the same dose of CBD did not affect IA memory consolidation under baseline conditions. However, CBD attenuated ANI-induced impairments in IA memory consolidation, and this protective effect was also blocked by K252a. Biochemical analyses further showed that ANI treatment reduced hippocampal mature BDNF levels, whereas CBD administration prevented this reduction. Discussion: These findings demonstrate that CBD differentially modulates IA memory reconsolidation and consolidation through distinct neurotrophic mechanisms. Specifically, the CBD-induced impairment of memory reconsolidation was associated with reduced hippocampal proBDNF levels, whereas the protective effect of CBD against ANI-induced deficits in memory consolidation was accompanied by restoration of mature BDNF expression relative to the vehicle control group. Collectively, these findings provide novel mechanistic insights into the bidirectional effects of CBD on memory processes and underscore the importance of carefully evaluating its therapeutic potential and associated neurobiological mechanisms in the context of memory-related disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.